Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 am ET. Keros specializes in developing novel treatments for hematological and musculoskeletal disorders with high unmet needs. Its lead candidates include KER-050 for cytopenias, KER-047 for anemia and fibrodysplasia ossificans progressiva, and KER-012 for bone loss disorders and pulmonary arterial hypertension.

LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Jasbir S. Seehra, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22^nd Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 am ET.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Investor Contact:
Julia Balanova
jbalanova@soleburytrout.com
646-378-2936

FAQ

When is Keros Therapeutics scheduled to present at the H.C. Wainwright conference?

Keros Therapeutics is scheduled to present on September 14, 2020, at 10:30 am ET.

What are the main product candidates of Keros Therapeutics?

Keros Therapeutics' main product candidates include KER-050 for cytopenias, KER-047 for anemia, and KER-012 for bone loss disorders.

What is KER-050 developed for?

KER-050 is being developed for the treatment of low blood cell counts, including anemia and thrombocytopenia.

What disorders does KER-012 target?

KER-012 is developed for disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta.

What role does Keros Therapeutics focus on in its research?

Keros Therapeutics focuses on the transforming growth factor-Beta (TGF-ß) family of proteins, which regulate red blood cell and platelet production.